Boehringer’s zongertinib receives Priority Review from U.S. FDA for the treatment of HER2 (ERBB2)-mutant advanced non-small cell lung cancer
Ridgefield, Conn., U.S., and Ingelheim, GermanyZongertinib would be the first orally administered, targeted therapy for previously treated ...
Chemomab completes End-of-Phase 2 Meeting with the FDA for CM-101
Chemomab Therapeutics (CMMB) announced the successful completion of its End-of-Phase 2 Meeting with the FDA and alignment with FDA on the ...